Molecular abnormalities in leukemic cells are important determinants of risk stratification in Pediatric acute lymphoblastic leukemia (ALL). TCF3-PBX1 fusion is one of the common aberrations in ALL with doubtful prognostic significance. Therefore, aim of our study is to revisit the clinical characteristics and outcome of this abnormality in children with ALL treated at our institute.Demographic, Clinical and treatment related characteristics of 539 newly diagnosed ALL patients from January 2009 and December 2018, < 18 years of age treated on BFM-95 protocol, was abstracted from the medical records. Clinical characteristics and outcome of children with and without TCF3-PBX1 fusion was compared.Incidence of TCF3-PBX1 fusion was observed in 24/539(4.4%) patients with a median age of 4 years (range 1–17). None of the patients in TCF3-PBX1 group had CNS or testicular disease at presentation. Day -8 prednisolone response and morphological remission at the end of induction was similar in both study groups. 5-year overall and event free survival for those with and without fusion was 75%, 70.1% and 79.5%, 69.5% respectively.The incidence of TCF3-PBX1 fusion in the present study was 4.4% and it does not have an independent prognostic significance.

白血病细胞的分子异常是小儿急性淋巴细胞白血病 (ALL) 风险分层的重要决定因素。TCF3-PBX1 融合是 ALL 中常见的畸变之一，其预后意义值得怀疑。因此，我们研究的目的是重新审视在我们研究所治疗​​的 ALL 儿童中这种异常的临床特征和结果。2009 年 1 月至 2018 年 12 月 539 例新诊断的 ALL 患者的人口统计学、临床和治疗相关特征，< 18 岁根据 BFM-95 协议治疗的年龄，是从医疗记录中提取的。有和没有 TCF3 的儿童的临床特征和结果-比较 PBX1 融合。在 24/539 (4.4%) 的中位年龄为 4 岁（范围 1-17）的患者中观察到 TCF3-PBX1 融合的发生率。TCF3-PBX1 组的患者在就诊时均未患有中枢神经系统或睾丸疾病。第-8 天的泼尼松龙反应和诱导结束时的形态学缓解在两个研究组中相似。融合和未融合患者的 5 年总体生存率和无事件生存率分别为 75%、70.1% 和 79.5%、69.5%。本研究中 TCF3-PBX1 融合的发生率为 4.4%，并且没有独立的预后因素意义。